Last Updated: May 3, 2026

TIVORBEX Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Tivorbex patents expire, and what generic alternatives are available?

Tivorbex is a drug marketed by Genus and is included in one NDA. There are three patents protecting this drug.

This drug has thirty-seven patent family members in twenty-one countries.

The generic ingredient in TIVORBEX is indomethacin. There are fifteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the indomethacin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tivorbex

A generic version of TIVORBEX was approved as indomethacin by CHARTWELL MOLECULES on August 6^th, 1984.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for TIVORBEX?
What are the global sales for TIVORBEX?
What is Average Wholesale Price for TIVORBEX?

Summary for TIVORBEX

International Patents:	37
US Patents:	3
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TIVORBEX

TIVORBEX is protected by three US patents.

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genus	TIVORBEX	indomethacin	CAPSULE;ORAL	204768-001	Feb 24, 2014		DISCN	Yes	No	9,089,471	⤷ Start Trial				⤷ Start Trial
Genus	TIVORBEX	indomethacin	CAPSULE;ORAL	204768-002	Feb 24, 2014		DISCN	Yes	No	9,089,471	⤷ Start Trial				⤷ Start Trial
Genus	TIVORBEX	indomethacin	CAPSULE;ORAL	204768-001	Feb 24, 2014		DISCN	Yes	No	8,734,847	⤷ Start Trial	Y			⤷ Start Trial
Genus	TIVORBEX	indomethacin	CAPSULE;ORAL	204768-001	Feb 24, 2014		DISCN	Yes	No	8,992,982	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for TIVORBEX

See the table below for patents covering TIVORBEX around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Morocco	33296	صيغة جديدة لإندوميثاسين	⤷ Start Trial
New Zealand	620879	A novel formulation of indomethacin	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2010121328		⤷ Start Trial
Japan	2015051995		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.